Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Biliary Tract Neoplasms 1

Interventions

Bevacizumab 119Fluorouracil 91Leucovorin 83Cetuximab 83Oxaliplatin 80pembrolizumab 70Irinotecan 67Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26Standard of Care 25HMPL-013 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19atezolizumab 18Trifluridine 18Cisplatin 18tislelizumab 17balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × CA-4948 × 1 year × Clear all
NCT06696768 2026-06-03

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡